CPA
IRON icon

Capital Performance Advisors’s Disc Medicine IRON Stock Holding History

Capital Performance Advisors’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$98 – 1387
2024
Q3 		$98 Buy
+2
New +$94 ﹤0.01% 2701

Other funds holding IRON

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Performance Advisors's IRON Position: Q4 2024 in Review

Capital Performance Advisors sold out of Disc Medicine (IRON) in Q4 2024, closing a stake of 2 shares — an estimated $98 sold.

Capital Performance Advisors first reported a position in IRON in Q3 2024 and held it in 1 quarter. The position peaked at $98 in Q3 2024. 152 funds tracked by Wall St. Rank hold IRON as of Q4 2024.

  • Capital Performance Advisors reported no remaining Disc Medicine position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 2 Disc Medicine shares in Q4 2024, an estimated $98.
  • Capital Performance Advisors first reported a position in Disc Medicine in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Disc Medicine position peaked at $98 in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Disc Medicine as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.